• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BTMD

    Biote Corp.

    Subscribe to $BTMD
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Biote Corp.

    DatePrice TargetRatingAnalyst
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    See more ratings

    Biote Corp. SEC Filings

    See more
    • Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - biote Corp. (0001819253) (Filer)

      5/7/25 4:06:53 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFR14A filed by Biote Corp.

      DEFR14A - biote Corp. (0001819253) (Filer)

      5/5/25 4:51:15 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Biote Corp.

      8-K - biote Corp. (0001819253) (Filer)

      4/24/25 4:15:30 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Biote Corp.

      EFFECT - biote Corp. (0001819253) (Filer)

      4/14/25 12:15:08 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POS AM filed by Biote Corp.

      POS AM - biote Corp. (0001819253) (Filer)

      4/9/25 5:00:56 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 filed by Biote Corp.

      S-8 - biote Corp. (0001819253) (Filer)

      4/9/25 4:27:59 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Biote Corp.

      DEFA14A - biote Corp. (0001819253) (Filer)

      4/3/25 4:56:01 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Biote Corp.

      DEF 14A - biote Corp. (0001819253) (Filer)

      4/3/25 4:53:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Biote Corp.

      SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)

      3/18/25 1:38:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Corp. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - biote Corp. (0001819253) (Filer)

      3/17/25 8:06:20 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    Biote Corp. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biote Corp.

      SC 13G/A - biote Corp. (0001819253) (Subject)

      11/12/24 4:15:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 5:17:02 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 2:11:05 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/13/24 4:38:50 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/13/24 3:36:17 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/12/24 4:23:01 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      6/23/23 1:11:59 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Biote Corp.

      SC 13D - biote Corp. (0001819253) (Subject)

      6/15/23 4:00:24 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Biote Corp.

      SC 13G - biote Corp. (0001819253) (Subject)

      6/13/23 4:05:14 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Biote Corp.

      SC 13G - biote Corp. (0001819253) (Subject)

      2/17/23 12:44:43 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    Biote Corp. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on biote Corp.

      Craig Hallum initiated coverage of biote Corp. with a rating of Buy

      12/16/24 8:50:55 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on biote Corp. with a new price target

      B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

      2/20/24 6:47:29 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on biote Corp.

      Jefferies initiated coverage of biote Corp. with a rating of Buy

      2/1/24 6:18:15 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    Biote Corp. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $25,906 worth of shares (7,874 units at $3.29) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/18/25 11:52:35 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $155,388 worth of shares (48,439 units at $3.21) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/10/25 4:43:27 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $237,406 worth of shares (74,440 units at $3.19) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/7/25 6:56:31 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Large owner Guines Llc bought $2,784,419 worth of shares (856,609 units at $3.25) (SEC Form 4)

      4/A - biote Corp. (0001819253) (Issuer)

      4/3/25 12:27:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $351,920 worth of shares (106,000 units at $3.32) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/2/25 6:06:59 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Executive Chairman Beer Marc D

      4 - biote Corp. (0001819253) (Issuer)

      4/2/25 4:35:20 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Peterson Robert Charles

      4 - biote Corp. (0001819253) (Issuer)

      4/2/25 4:34:58 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    Biote Corp. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Biote Corp. Financials

    Live finance-specific insights

    See more

    Biote Corp. Leadership Updates

    Live Leadership Updates

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $25,906 worth of shares (7,874 units at $3.29) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/18/25 11:52:35 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $155,388 worth of shares (48,439 units at $3.21) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/10/25 4:43:27 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $237,406 worth of shares (74,440 units at $3.19) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/7/25 6:56:31 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Large owner Guines Llc bought $2,784,419 worth of shares (856,609 units at $3.25) (SEC Form 4)

      4/A - biote Corp. (0001819253) (Issuer)

      4/3/25 12:27:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $351,920 worth of shares (106,000 units at $3.32) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/2/25 6:06:59 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Heyer Andrew R bought $296,042 worth of shares (75,000 units at $3.95), increasing direct ownership by 3% to 1,523,513 units (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      3/19/25 8:27:14 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Christensen Bret bought $145,493 worth of shares (37,595 units at $3.87) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      3/18/25 7:45:45 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of

      2/26/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Third Quarter 2024 Financial Results

      Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per

      11/12/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will

      10/29/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Second Quarter 2024 Financial Results

      Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt

      8/8/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast wi

      7/25/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports First Quarter 2024 Financial Results

      Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $46.8 million, up 4.4% Procedure revenue of $37.4 million, up 6.6% Gross profit margin of 71.4%, an approxima

      5/7/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Tuesday, May 7, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Biote to Purchase Asteria Health

      Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

      1/17/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Names Robert Peterson as Chief Financial Officer

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

      1/11/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Appoints Mary J. Puncochar as Chief Commercial Officer

      Ms. Puncochar to Drive Execution of Biote's Strategic Sales and Marketing Initiatives biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biot

      5/30/23 8:30:00 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    Biote Corp. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Announces Purchase of Shares by Directors and CEO

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote's common stock, acquiring an aggregate of approximately 260,000 shares. Marc Beer, Biote Executive Chairman, said, "These share purchases underscore the collective confidence of Biote's Board members and CEO Bret Christensen in the Company's business strategy and long-term outlook. The board is very confident in Bret's ability to make decisive and material changes a

      3/18/25 5:30:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of

      2/26/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • AccessHope Expands Executive Leadership Team Amid Rapid Growth and Upcoming Market Expansion

      Duke University Oncologist and former Optum Executive Dr. Yousuf Zafar Named Chief Medical OfficerVeteran Digital Health and Commercial Leader Peter Bridges to Serve as Chief Strategy and Growth OfficerDebra Morris Promoted to PresidentDUARTE, Calif., Nov. 13, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it is expanding its executive leadership team in response to growing demand for the company's personalized cancer benefit and upcoming product expansion. Yousuf Zafar, MD, MHS, a widely published practicing oncologist from Duke University who brings expertise in value-based care and precision medicine, will

      11/13/24 9:00:00 AM ET
      $BTMD
      $REXR
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • Biote Reports Third Quarter 2024 Financial Results

      Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per

      11/12/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will

      10/29/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Second Quarter 2024 Financial Results

      Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt

      8/8/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care